Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 10/20 | 0.72 |
| ▸ | CDK4 | P11802 | 5/20 | 0.72 |
| ▸ | CCND2 | P30279 | 2/20 | 0.72 |
| ▸ | CCND3 | P30281 | 2/20 | 0.72 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.69 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.69 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.69 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.59 |
| ▸ | CDK2 | P24941 | 9/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.59 |
| ▸ | CDK9 | P50750 | 3/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24670367 | 1.00 | CCND1 (0.72) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL16802596 | 0.90 | MAPK8 (0.82) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL18160381 | 0.88 | MAPK8 (0.58) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL18148245 | 0.87 | MAPK8 (0.73) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL3305016 | 0.87 | MAPK8 (0.73) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL16802606 | 0.87 | MAPK8 (0.73) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL16799550 | 0.87 | MAPK8 (0.73) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL7794897 | 0.87 | MAPK8 (0.73) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL16802597 | 0.86 | MAPK8 (0.67) | CCND1CDK4CCND2CCND3MAPK8 | |
| SCHEMBL22787390 | 0.84 | MAPK8 (0.60) | CCND1CDK4CCND2CCND3MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | claimed |
| WO-2015084936-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-11 | — | — | WO | disclosed |
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | disclosed |
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | disclosed |
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | MAP3K20, MAP3K6, MAP3K1 | CCND1 506/4885CDK4 168/4885CCND2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.